Platelet Reactivity With Fentanyl, Morphine, or no Narcotic

Fentanyl Clinical Trial

Official title:

A Comparison of PLAtelet Response to Aspirin Between Emergency Department Patients With Chest Pain Receiving Fentanyl or Morphine (PLAAFM)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05367336
• Other study ID #: EGME#04-2021
• Status: Recruiting
• Phase: Early Phase 1
• Start date: August 31, 2022
• Est. completion date: May 2024

Study information

• Verified date: October 2023
• Source: Spectrum Health - Lakeland
• Contact: Monique Luna
• Phone: 2699858679
• Email: monique.allen[@]spectrumhealth.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal is to determine whether fentanyl and morphine have similar effects in reducing aspirin's effect upon platelets in emergency department patients with chest discomfort. Morphine has been shown to worsen outcomes in heart attack patients due to reduction of oral anti-platelet agent effectiveness and so many providers have switches to using fentanyl. However, it is largely unknown whether fentanyl has similar effects.

Description:

Patients presenting to the emergency department with chest discomfort who are being administered aspirin will be offered enrollment in this study. At the time of their zero and two hour troponin we will also draw platelet aggregration studies to determine the effects of aspirin upon platelets. Narcotic medicines slow the absorption of aspirin. Morphine has therefore been shown to decrease the effectiveness of aspirin. Many providers therefore use fentanyl instead, however little is known about the effects of fentanyl upon aspirin. We will therefore compare the platelet reactivity of patients receiving morphine, fentanyl, or no narcotics

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: May 2024
• Est. primary completion date: May 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Adult Emergency Department patients undergoing 0 and 2 hour troponin testing

• administered aspirin within 30 minutes of the initial blood draw.

• patient presented via private vehicle

• provide informed consent

Exclusion Criteria:

• Patients not expected to get a 2 hour troponin;

• patients already on aspirin, clopidogrel, or stronger anti-coagulants;

• patients who arrived via EMS (Emergency Medical Services) given it can be difficult to find the run reports to determine whether patient received fentanyl in the pre-hospital period;

• pregnant patients;

• patients on chronic narcotics;

• patients already once enrolled in this study,

• inability to provide consent in English

Related Conditions & MeSH terms

• Fentanyl
• Platelet Reactivity

Intervention

Drug:
• Morphine
second group will be receiving morphine
• Fentanyl
third group receiving fentanyl

Locations

Country	Name	City	State
United States	Spectrum Health Lakeland	Saint Joseph	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Spectrum Health - Lakeland

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	platelet aggregation	arachidonic acid platelet aggregation activity	2 hours